The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
USFDA inspection at Alembic Pharma's Bioequivalence facility
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Branded formulation business continues to perform well across domestic and export markets
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
